Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Evan Adler

Podiatrist, Foot & Ankle Surgery Old Bridge, NJ Doctor of Podiatric Medicine

NPI 1740425644 CMS profile 124920

400 Perrine Rd Ste 408, Evan Adler DPM, Old Bridge, NJ 08857

Open in the dashboard

General payments

$195,100

440 records reported · program years 2019–2025

Research payments

$3,900

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evan Adler of Old Bridge, NJ is reported in the CMS Open Payments database as having received $195,100 across 440 general payments and $3,900 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,936 37
2024 General $16,709 50
2023 General $47,312 78
2022 General $27,065 82
2021 General $42,403 70
2020 General $20,929 40
2020 Research $3,900 1
2019 General $38,744 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evan Adler
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Evan Adler were reported at $1,936. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Evan Adler Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $38,744 $389 $118–$1,406 $163
2020 $20,929 $191 $62–$691 $114
2021 $42,403 $329 $104–$1,341 $132
2022 $27,065 $419 $125–$1,611 $149
2023 $47,312 $377 $128–$1,164 $160
2024 $16,709 $394 $134–$1,168 $164
2025 $1,936 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $187,801 214 payments
  2. Stryker Corporation $2,385 48 payments
  3. Wright Medical Technology, Inc. $1,353 14 payments
  4. Organogenesis Inc. $806 38 payments
  5. Smith+Nephew, Inc. $616 43 payments
  6. Integra LifeSciences Corporation $363 5 payments
  7. DePuy Synthes Sales Inc. $275 7 payments
  8. Paratek Pharmaceuticals, Inc. $239 16 payments
  9. AbbVie, Inc. $159 3 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $137 9 payments
  11. Other $968 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $166,327 58 payments
  2. Travel and Lodging $17,755 67 payments
  3. Food and Beverage $10,882 313 payments
  4. Entertainment $136 2 payments
Products named General payments · program years 2019–2025
  1. PROPHECY $770 2 payments
  2. AUGMENT INJECTABLE $638 9 payments
  3. VARIAX $526 11 payments
  4. Puraply $449 22 payments
  5. PROSTEP MICA $351 8 payments
  6. PRIMATRIX $350 4 payments
  7. INTEGRA DERMAL REGENERATION TEMPLATE $350 4 payments
  8. INFINITY $349 7 payments
  9. Integra Recon-Skin And Wound $330 3 payments
  10. Integra Recon-Skin And Wound $330 3 payments
  11. Other $4,556 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $3,900 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

122

Median for Podiatry: 160

Drug cost

$54,372

Median for Podiatry: $2,368

Branded share of claims

35.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 16 $44,252
Jublia Efinaconazole Brand 13 $9,464
Gabapentin Generic 15 $279
Doxycycline Hyclate Generic 18 $143
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $87
Methylprednisolone Generic 17 $83
Triamcinolone Acetonide Generic 12 $50
Meloxicam Generic 17 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$4,743,070

Of which drugs: $4,474,230

Medicare patients

496

Average age 75

Services billed

5,254

269 women, 227 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 52%
Ischemic heart disease 49%
Chronic kidney disease 36%
Atrial fibrillation 33%
Heart failure 28%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Amnio quad-core, per square centimeter Q4294 Office 18 1,203 $2,114,046
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 16 $11
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 16 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $76
$76 — —
KRYSTEXXA
  • Amgen Inc. $45
$45 — —
JUBLIA
  • Ortho Dermatologics, a division of Bausch Health US, LLC $17
$17 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record